Jan 29 (Reuters) - BERGENBIO ASA:
* BERGENBIO: ENCOURAGING I-O CLINICAL DATA WITH SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB324) SUPPORTS ITS POTENTIAL AS CORNERSTONE OF CANCER THERAPY
* ‍FAVOURABLE INTERIM SAFETY DATA REPORTED ACROSS THREE PHASE II CLINICAL TRIALS WITH BEMCENTINIB IN COMBINATION WITH KEYTRUDA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 